Introduction
The neuregulin-1 (NRG1) gene has been proposed both as a candidate oncogene and as a candidate tumour suppressor gene. It seems likely to have a role in epithelial cancers, because it encodes ligands that bind to the ERBB/HER/EGFR family of receptors. These ligands, originally known as heregulin-a and heregulin-b, neu differentiation factor (NDF), sensory and motor neuron-derived factor (SMDF) and glial growth factor II, are made by alternative splicing, and include forms that are transmembrane, externally membrane bound, shed, secreted or intracellular (Falls, 2003; Hayes and Gullick, 2008) . They bind to ERBB3 or ERBB4, which probably signal as heterodimers with ERBB2 (HER2).
Although the NRG1-encoded proteins are usually thought of as mitogens, they can also be powerfully proapoptotic: in particular, expressing NRG1 in cells can cause apoptosis of the expressing cell .
The NRG1 gene has been identified as a potential cancer-critical gene in two, apparently contradictory, contexts. First, it is the prime candidate for the major tumour suppressor gene thought to be on 8p, the short arm of chromosome 8. Loss of 8p is one of the most frequent genomic events in epithelial cancers, including breast, colon, bladder and prostate. This has been shown successively by loss of heterozygosity, comparative genomic hybridization (CGH) and array-CGH studies (for references, see Birnbaum et al., 2003; Pole et al., 2006) . The classical interpretation of this loss of 8p would be that there is a tumour suppressor gene there. We previously mapped the 8p losses in carcinoma cell lines using fluorescence-in situ hybridization and array-comparative genomic hybridization (array-CGH) and found that almost all breaks were proximal to, or actually within NRG1, making NRG1 and genes immediately telomeric to NRG1 the prime candidates for such a tumour suppressor (Pole et al., 2006; Cooke et al., 2008) .
Second, NRG1 could be an oncogene because it seems to be the target of chromosome translocations in breast cancer. In the breast cancer cell line MDA-MB-175, a translocation has fused the 3 0 end of NRG1, including the receptor-binding domain, downstream of ODZ4/ DOC4, creating a secreted protein with biological activity (Schaefer et al., 1997; Liu et al., 1999; Wang et al., 1999) . Along with other researchers, we showed that there are breakpoints within NRG1 in a number of other breast cancer cell lines and in around 6% of breast tumours, all preserving the 3 0 end of the gene Huang et al., 2004; Prentice et al., 2005) . One interpretation of this is that NRG1 is activated by fusion or promoter insertion. However, other explanations have been suggested (see the section 'Discussion'; Weinstein and Leder, 2000; Birnbaum et al., 2003; Prentice et al., 2005) .
In this study, we analysed the role of NRG1 in breast cancer, beginning with measuring expression of NRG1 in normal breast and breast cancers.
Results
Neuregulin-1 (NRG1) transcription start sites and exon usage in breast To quantitate the expression of NRG1, which has many alternative splice forms (Figure 1a ; Falls, 2003) , preliminary reverse transcriptase-PCR experiments (not shown) were carried out, to find which of the three main transcription start sites were used in the cell lines, and whether there were major variations in exon usage. These experiments showed that, generally, when a cell line expressed any NRG1, all exons tested were expressed, except exon 1. This implied that the exon 1 transcription start site was not used in these samples and that the transcription was from the start sites in exons 2 and 7 ( Figure 1a ). In addition, the pattern of exon usage was rather similar across the samples. This allowed us to broadly quantitate NRG1 expression using a single PCR primer pair that spanned exons 4-6, which are in almost all transcripts initiated in exon 2.
One exception requires comment. In MDA-MB-175, the expression of all exons except exons 1 and 2 was detected. This line expresses a fusion of NRG1 that splices in at exon 3. Although the fusion complementary DNA (cDNA) that was originally described lacked the transmembrane and cytoplasmic domains (Schaefer et al., 1997) , we detected all the 3 0 exons that we tested for, and hence the fusion gene expresses alternative isoforms including the intracellular domains, as also found by Ade´laı¨de et al. (2003) .
Expression of neuregulin-1 (NRG1) is low in breast cancers Quantitative PCR using the primer pair spanning exons 4-6 showed that many breast cancer cell lines expressed little or no NRG1 (Figure 1b ), whereas the normal mammary epithelium, both as cell lines (Figure 1 ) and as cells (see below), did express NRG1. Similar results were obtained with a primer pair in exon 8, which encodes the receptor-binding domain and is included in almost all isoforms, but is short and a poor target for PCR ( Supplementary Figure 1a) .
Western blotting was consistent with the mRNA expression data: a single major band of B75 kDa was seen in the normal breast cell line HB4a and in the cancer lines that showed substantial mRNA expression ( Supplementary Figure 1b ), whereas no band was detected in T-47D, a representative line that expressed no mRNA. 75 kDa is the expected size for intact heregulins (see, for example, Deadwyler et al., 2000) , all of which are expressed from exon 2.
A similar pattern was seen when NRG1 mRNA expression was measured in breast tumour samples, and in cells and tissue from normal breast (Figure 2a ). The highest expression was seen in purified myoepithelial cells and normal breast epithelial 'organoids', that is, intact, uncultured epithelial fragments made up of both myoepithelial and luminal epithelial cells, isolated by collagenase digestion of the breast tissue (Edwards et al., 1986) . Purified luminal cells and commercial RNA from long-term primary cultures expressed less. Among the tumours, three of six samples of purified tumour cells from pleural or ascitic effusions showed essentially no expression. Tumour tissue samples showed a range of expression, mostly equal to or less than the normal samples, with 25% of the 58 samples expressing less than any of the normal samples. Some of this expression may well be from stromal cells, which are typically 30% or more of the cells present, and hence it is possible that many of the tumours have lost the expression of NRG1, as for the cell lines. Falls (2003) with introns not to scale. The arrows mark the major transcription start sites at exons 1, 2 and 7 (for additional transcript start sites and exons, see Steinthorsdottir et al., (2004) ). Arrowheads, primer sites in exons 4 and 6 used for quantitative PCR shown in (b). CpG, CpG island identified at exon 2. Underneath, the CpG island: thin line, whole island, thick line, section analysed for methylation by cloning and sequencing, with positions relative to the translation start site of exon 2 (ATG at 32 525 787 bp on the reference genome sequence Builds 35 and 36). Below this the 29bp sequence selected for pyrosequencing, with the six cytosines of CpGs marked with a circle. (b) The expression of NRG1 in cell lines. Top panel, expression by real-time quantitative reverse transcriptase-PCR (RT-PCR) using primers shown in (a), relative to normal breast luminal epithelial cell line, HB4a, on a linear scale. Open bars, lines from non-cancer breast; grey bars, cancer cell lines in the order of decreasing expression. Cell lines marked with an asterisk have translocation breaks within NRG1, all of which preserve the 3 0 end of the gene. (c) Methylation levels over the CpG island (shown in a), determined by conventional bisulphite sequencing. In these histograms, vertical lines represent the number of methylated copies of individual CpGs in 10 clones, plotted against genomic position. The left-hand group of lines have some expression and low methylation, the middle group shows little expression and little methylation and the right-hand group shows little expression and high methylation. The brackets below the methylation histograms show the region selected for pyrosequencing in Figure 2 .
The CpG island in neuregulin-1 (NRG1) is methylated in breast cancer cell lines We therefore investigated whether NRG1 expression might be silenced by DNA methylation. Bisulphite sequencing analysis of the CpG island around the exon 2 transcription start site ( Figure 1a ) showed that it was heavily methylated in 10 of 19 (53%) breast cancer cell lines tested, whereas the remaining lines and the non-cancer breast cell lines, HB4A and HMT-3552, showed little methylation ( Figure 1c ).
Methylation correlated closely with an absence of NRG1 transcripts (Figures 1b and c ). The 10 breast cancer cell lines with methylation showed no expression, whereas the lines with NRG1 transcripts had low DNA methylation. A further small group of breast cancer cell lines, MDA-MB-157, UACC 812, HCC 1187 and Silencing of the NRG1 gene in breast cancer YL Chua et al SUM52, lacked NRG1 transcripts and had low DNA methylation at the CpG island, suggesting that NRG1 can also be inactivated by mechanisms other than DNA methylation.
Azacytidine treatment
Two cell lines that had heavy CpG island methylation, HCC 1500 and MDA-MB-361, were treated with the demethylating agent, 5-aza-2 0 -deoxycytidine. The treat-ment activated transcription of NRG1 ( Supplementary  Figure 2 ).
Neuregulin-1 (NRG1) is methylated in tumours but not in normal breast tissue To quantitate methylation in a panel of tissue samples, we used pyrosequencing of bisulphite-treated DNA (Yang et al., 2004) . A 29-bp sequence was selected from the CpG island (Figure 1a ), which included six CpGs Figure 1b ) normalized to the average of all samples, log2 scale. Tumour tissues are the Nottingham series of breast tumour tissue samples, with median and interquartile values shown as lines adjacent to datapoints; 'effusions (pure tumour)' are pure breast tumour cells from five pleural and one ascitic effusions. Normals are RNA from normal breast tissue; myo/basal and luminal cells, respectively, purified basal/myoepithelial and luminal cells from normal breast; and organoids, uncultured epithelial fragments from normal breast. (b) DNA methylation in tumours (with median and interquartile lines), purified tumour cells from effusions and normal breast organoids, that is, epithelial fragments prepared from normal breast. Representative cell lines are also shown, for comparison, re-analysed by pyrosequencing. Methylation, detected by pyrosequencing of uncloned bisulphite-treated DNA, is expressed as the percentage of methylation averaged over the six CpGs pyrosequenced. (c) NRG1 expression as a function of DNA methylation. The tumour tissue samples are divided according to whether they show genomic loss of 8p, including NRG1, by array-CGH. Dotted circle, 'outliers', that is, samples with low expression in the absence of methylation (all outlier tumour tissue samples had 8p loss). The solid line is the regression line for all the tumour tissue samples, excluding the outliers (50 tumours, y ¼ À0.049x þ 0.75, rp0.19, slope significantly less than zero, P ¼ 0.0017); dotted line is for the samples with 8p loss excluding outliers (18 tumours, y ¼ À0.078x þ 1.9, rp0.42, slope significantly less than zero, P ¼ 0.0036). that were always methylated in breast cancer cell lines that showed methylation, but were un-methylated in non-cancer breast lines ( Figure 1c ).
No DNA methylation at NRG1 was detected in uncultured, normal breast epithelium (Figure 2b ), obtained in the form of 'organoids'.
In contrast, many tumours showed substantial DNA methylation of the 29-bp sequence, with the methylation averaging 24% or more in half of the 59 tumour tissue samples (Figure 2b ). Average methylation ranged from 0 to 60%, the upper limit of 60% presumably reflecting the presence of normal cells in the samples. To address this issue, purified tumour cells from six pleural or ascitic effusions were also analysed ( Figure 2b ). One pleural effusion sample showed substantial methylation, averaging about 40% over the pyrosequenced CpGs.
When methylation of this six-CpG sequence was compared with the expression of NRG1, there was a trend of a decrease in NRG1 expression with increase in DNA methylation (Figure 2c ). More precisely, Figure 2c suggests that, as for the cell lines, some tumours have NRG1 expression reduced by methylation, whereas others have NRG1 silenced by other mechanisms. The latter group would be those with low expression but little or no methylation (circled in Figure 2c ). If these cases were set aside, the correlation between lower expression and increasing methylation was clear and highly significant.
As NRG1 may be a tumour suppressor that is inactivated by a two-hit mechanism, with one hit often being the loss of distal 8p, it was interesting to divide the tumours according to whether they had lost 8p, using existing array-CGH data (Chin et al., 2007) . There was no profound difference in expression and methylation between the tumours with and without 8p loss, but the 18 tumours with 8p loss showed a tighter correlation between expression and methylation, when the outlier group was excluded ( Figure 2c ).
Knockdown of neuregulin-1 (NRG1) can increase net cell proliferation These observations suggested that downregulating NRG1 expression in mammary epithelial cells might give cells a survival advantage. We reduced NRG1 expression by stable expression of small interfering RNA (siRNA) constructs in the normal breast luminal epithelial cell line HB4a, and in HCC1806, a breast cancer cell line that expresses a relatively high level of NRG1 (Figure 1b ). Multiple siRNA constructs were designed, giving three independent siRNA treatments for HB4a and two treatments for HCC1806.
The net proliferation was modestly but consistently increased, independent of the siRNA construct used, even though only a modest reduction of expression was seen ( Figure 3 ). This result, together with the methylation data, suggests that NRG1 acts as a tumour suppressor.
Expression of receptors for neuregulin-1 (NRG1) To aid interpretation of our NRG1 data, we also measured the expression of ERBB2, ERBB3 and ERBB4 in our cell line panel ( Supplementary Figure 3 ). There was a strong negative association between NRG1 expression and high ERBB-family expression ( Figure 4) : the few breast cell lines with near-normal or raised NRG1 expression had low or negligible expression of ERBB2, ERBB3 and ERBB4, whereas the lines that showed high expression of any ERBB gene expressed little or no NRG1. The lines that did express some NRG1 together with raised ERBB2, ERBB3 and/or ERBB4 were HCC1806, MDA-MB-175, HCC1937 and ZR-75-1, all of which had breaks in NRG1, and CAMA-1 for which the genomic structure of NRG1 is not known.
Discussion
Our findings suggest that NRG1 is frequently inactivated in breast cancer and behaves as a tumour suppressor. NRG1 was expressed in the normal human breast, by both luminal and myoepithelial cells, whereas in many breast cancer cell lines there was little or no expression. The absence of expression was often associated with DNA methylation of the CpG island at the principal transcription start site for NRG1 in cell lines, and most tumours also showed DNA methylation. Reducing NRG1 expression in cell lines increased net cell proliferation. Others researchers have shown that expressing NRG1 in a breast cancer cell line by transfection causes apoptosis .
Neuregulin-1 (NRG1) in normal breast
We found that both luminal and basal/myoepithelial cells in non-pregnant human breast epithelium express NRG1. Previous data on NRG1 expression in normal mammary gland do not give a clear picture. In the mouse, Yang et al. (1995) reported that the NRG1 isoform, heregulin-a, was expressed by the stroma in late pregnancy, implying that there was little expression in the epithelium, particularly in non-pregnant epithelium. However, Schaefer et al. (1997) reported expression from normal human breast tissue (and absence in several breast cancer cell lines), and Aguilar et al. (1999) and Ade´laı¨de et al. (2003) reported expression of NRG1 mRNA in cultured normal human mammary epithelial cells, which are likely to be predominantly basal/myoepithelial cells (Clarke et al., 2005) .
In vivo experiments on the role of NRG1 in mouse mammary gland seem to have neglected the resting mammary gland (Britsch, 2007) . Attention has been focussed on heregulin-a's critical role in late pregnancy and lactation, already mentioned (Yang et al., 1995) . This is supported by several findings: the activated rat ERBB2, neu T , when introduced into mammary epithelium caused development of clusters of alveolar-like structures (Bradbury et al., 1993) ; heregulin implants in the gland stimulated duct branching (Jones et al., 1996) ; and a knockout mouse with a stop codon in exon 9 of NRG1, preventing translation of a-isoforms, had retarded lactational development (Li et al., 2002) .
One proposed role for NRG1 in epithelia in general, consistent with it being implicated in cancer 
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Silencing of the NRG1 gene in breast cancer YL Chua et al development, is as a mediator of wound healing (Vermeer et al., 2003) . At least in human airway epithelium, NRG1 protein is produced at the apical face of the polarized epithelium whereas its receptor(s) are basolateral, so that NRG1 signalling would indicate breaching of the epithelium (Vermeer et al., 2003) . Histology shows that malignant epithelium is often, perhaps always, defective in the ability to restore a single, intact epithelial surface, implying a defect in wound healing.
The significance of translocation breakpoints in neuregulin-1 (NRG1) One postulated role of NRG1 was as an oncogene activated by chromosome translocation in breast cancers. Our data do not support this in general. As noted in the 'Introduction' section, about 6% of breast tumours have translocations or other genome rearrangements with breakpoints within NRG1, retaining the 3 0 end of the gene (Huang et al., 2004) , and in one cell line, MDA-MB-175, the translocation produces a fusion protein ODZ4-NRG1. This raised the possibility that NRG1 expression was activated in breast tumours by translocation. However, seven of the cell lines used here have a translocation breakpoint within NRG1 (Table 1) , and they did not show increased expression: two had equivalent expression to the normals, two had substantially less and three had no detectable expression ( Table 1 ). The one cell line in our whole set that showed slightly increased expression compared with normal epithelium, MDA-MB-415, is not known to have a rearrangement of the NRG1 region, and no rearrangement was detected by fluorescence-in situ hybridization using bacterial artificial chromosome probes (not shown) or array-CGH (Pole et al., 2006) . Similarly, in the tumours there was no population with dramatically increased expression. The breakpoints in NRG1 may therefore in most cases inactivate one copy of the gene. The gene is extremely large, so the prevalence of breaks within the gene is not particularly surprising (Birnbaum et al., 2003; Prentice et al., 2005) .
There may of course be cases in which translocation creates an abnormal, or abnormally regulated NRG1 product. To date the MDA-MB-175 cell line is the only case with a translocation that is known to result in a fusion gene. It is not known whether the fusion product has modified activity. Weinstein and Leder (2000) suggested that it might not have the pro-apoptotic activities of wild-type NRG1, because the original cDNA clone of the fusion transcript lacked the cytoplasmic, pro-apoptotic exons. However, along with Ade´laı¨de et al. (2003) , we detected expression of the cytoplasmic exons, and hence this specific mechanism seems unlikely.
Methylation of the neuregulin-1 (NRG1) CpG island in breast cancers
Our data suggest that many breast tumours have silenced NRG1 by aberrant methylation of the CpG island. Many breast cell lines had large numbers of methylated CpGs in the CpG island at the major transcription start of NRG1. Partially removing methylation in two cell lines that expressed no NRG1 restored some expression. Breast tumours, because they contain 30% or more normal cells, give less clear data, but half Figure 3 Net cell proliferation is enhanced by knockdown of neuregulin-1 (NRG1). Two cell lines that express NRG1 were stably transfected with various small interfering RNA (siRNA) constructs, resulting in a modest reduction in mRNA, typically around 50%. The expression of ERBB2, ERBB3 and ERBB4 compared with the expression of neuregulin-1 (NRG1). As in Figure 1 , expression levels were measured using real-time reverse transcriptase-PCR (RT-PCR) and are shown on a linear scale relative to the expression in the normal breast line HB4a, except for ERBB3, where the expression is relative to non-cancer breast line HMT3522, as the expression in HB4a is exceptionally low (8% of HMT3522). The ERBB4 expression was measured separately for each splice variant using isoform-specific primers: ERBB4 transcripts can include either the jma or jmb exon, though, in breast and breast cancer, the jma form predominates; and either include the CYT1 exon or skip it (giving CYT2 forms) (Muraoka-Cook et al., 2008; Sundvall et al., 2008) . For complete data, see Supplementary Figure 3 . The datapoints off-scale for ERBB4 are for Cama-1, with values about 100-to400-fold HB4a levels; and the points off-scale for NRG1 are for MDA-MB-415, with values fourfold HB4a.
Silencing of the NRG1 gene in breast cancer YL Chua et al showed 24% or more methylation averaged over six CpGs. No methylation was detected in purified, uncultured epithelium from normal breast, and hence no substantial population of breast epithelial cells is normally DNA-methylated at NRG1. This is consistent with a genome-wide survey of CpG island methylation in 13 normal tissues (including several epithelia but not mammary gland), which found little methylation of this CpG island except light methylation in peripheral blood cells (Rakyan et al., 2008) . An alternative interpretation might be that NRG1 is silenced by normal differentiation-specific methylation (see, for example, Takizawa et al., 2001; Ching et al., 2005) in a small population of epithelial cells in mammary gland that gives rise to tumours. Mammary epithelium comprises several cell types: the outer basal/ myoepithelial cells and the inner luminal cells, and there are subpopulations of luminal cell (Kalirai and Clarke, 2006) . However, this would not explain why some of the breast tumour cell samples showed low NRG1 expression without any methylation. We prefer the interpretation that methylation is abnormal and is one of the various ways of silencing the gene.
Breast cancer cell lines have been tentatively classified by gene expression into the subsets recognized for breast cancers: luminal-like, basal-like, and so on (Charafe-Jauffret et al, 2006; Neve et al, 2006) . Most of our lines are luminal-like, but there was no obvious relationship between this classification and NRG1 expression, breakpoints within NRG1 or methylation (Table 1) .
Neuregulin-1 (NRG1) has antiproliferative activity Although proteins encoded by NRG1, such as the heregulins, are thought of as mitogenic, they can also be strongly pro-apoptotic, particularly to the cell that expresses the gene. Leder and coworkers showed that the forced expression of NRG1 causes apoptosis in various cell lines, including MCF7, a breast cancer cell line that does not express NRG1 . This is a potent activity, because they had discovered it in an unbiased screen for pro-apoptotic cDNAs in HEK293 cells, in which NRG1 was the only hit (in an incomplete screen) (Grimm and Leder, 1997) . Proapoptotic activity was independent of ERBB-family receptors and required the C-terminus of NRG1, emphasizing that the action was on the expressing cell Weinstein et al., 1998) . Exogenous NRG1 proteins can also be antiproliferative under certain conditions (see, for example, Amin et al., 2005; Muraoka-Cook et al., 2006) .
Our siRNA experiments suggest a net antiproliferative effect of NRG1 expression in our system: downregulating NRG1 expression in two cell lines, HB4a and The breakpoint position for UACC812 is only approximate .
Silencing of the NRG1 gene in breast cancer YL Chua et al HCC1806, enhanced the net cell proliferation. These siRNA results were likely to be a specific effect, because it is unlikely that off-target effects would increase proliferation, and independent constructs gave similar results. At least some of this antiproliferative signalling may be extracellular (autocrine or cell-to-cell), because there was a strong negative association between NRG1 expression and the expression of ERBB2, ERBB3 and ERBB4 (Figure 4 ).
Neuregulin-1 (NRG1) could be the major tumour suppressor on 8p
The provocative interpretation of our results is that NRG1 is the long-sought tumour suppressor gene on 8p. Loss of, and/or homozygosity for, distal 8p is one of the most common genomic changes in carcinomas (see the 'Introduction' section). This suggests that there is a major tumour suppressor gene on 8p, but no convincing candidate has been found (Birnbaum et al., 2003; Cooke et al., 2008) . We have previously shown that the breakpoints leading to 8p loss are almost all within or proximal to NRG1, consistent with NRG1, or a gene immediately telomeric to NRG1, being a tumour suppressor gene that drives these losses (Pole et al., 2006; Cooke et al., 2008) . The next most telomeric gene, WRN, is not a good candidate, although it has been reported to be methylated (Agrelo et al., 2006) , as the loss of WRN compromises telomere replication (Crabbe et al., 2007) .
Conclusion
In conclusion, we suggest that NRG1 may be the principal tumour suppressor gene that leads to the loss of 8p in many breast and other epithelial cancers. NRG1 expression seems to be silenced in most breast cancers compared with the main types of mammary epithelial cell-this could be because tumours arise from a specialized population in which NRG1 is normally silenced, but we prefer the interpretation that NRG1 is silenced by aberrant methylation or other-as yet unknown-events such as promoter mutation. Expression of NRG1 in mammary cells is antiproliferative to the cells that express it, and array-CGH identifies NRG1 as the gene most likely to be a principal 8p tumour suppressor.
Materials and methods
Cell lines, tumours and normal breast tissue Cancer cell lines were as described (Pole et al., 2006) . The noncancer lines were from the originators: HB4a is a line immortalized from purified breast luminal epithelial cells (Stamps et al., 1994) and the HMT3522 line was from fibrocystic (non-cancer) breast (Briand et al., 1987) .
The breast tumours were 63 primary operable invasive breast cancers from the Nottingham City Hospital Tumor Bank, which we have extensively profiled (see, for example, Garcia et al., 2005; Chin et al., 2007; Naderi et al., 2007) . Both cDNA and genomic DNA were available for 54 tumours; a further four had cDNA alone and five had genomic DNA alone.
Six samples of pure breast tumour cells were from one ascitic and five pleural effusions collected at the University College Hospital, London. They were chosen for their high tumour-cell content and treated with red blood cell lysis buffer if heavily contaminated with blood. To purify the tumour cells, macrophages and reactive mesothelial cells were removed by exploiting their rapid adhesion to tissue culture plastic. Cells were incubated in L-15 medium/ 5% fetal calf serum for 2 h at 37 1C in large flasks, and then the unattached tumour cells were aspirated to give 495% tumour cells (MJ O'Hare and RC Stein, unpublished data).
Normal breast from reduction mammoplasty was obtained, with informed consent, from patients aged 18-38 years. The epithelial fragments, 'organoids', were prepared by collagenase digestion of tissue without culturing (Edwards et al., 1986) . Purified luminal and myoepithelial cells were prepared from primary cultures (initiated from organoids) that had been trypsinized and fractionated using antibodies and magnetic bead technology (Grigoriadis et al., 2006) .
Reverse transcriptase-PCR
The RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA), treated with DNaseI (DNA-free kit, Ambion Division, Applied Biosystems, Foster City, CA, USA) to remove genomic DNA, and was reverse transcribed using oligo-dT primers and Superscript III (Invitrogen). Real-time reverse transcriptase-PCR for NRG1 exons 4-6 was performed using primers HrgPCRE4F1 (CATTAACAAAGCATCAC TGGCT) and hrg3_6R1 (TGAAGAAGTATTTGCTCCTT); the primers for exon 8 were HRGE8F1, CTACATCTACAT CCACCACTGG and HRGE8R2, TTGCACAAGTATCTCG AGGGGT (chr8:32705009 þ 32705138). SYBR Green PCR Master Mix (Applied Biosystems) was used in an ABI 7900 (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a reference transcript, using the primers GAPDH_1F (GCAAATTCCATGGCACCGT) and GAPDH_1R (TCGCCCCACTTGATTTTGG). The primers for ERBB2, ERBB3 and isoform-specific primers for ERBB4 are given in Supplementary Figure 3 . In preliminary experiments using conventional reverse transcriptase-PCR, primer pairs were designed within all 17 exons except exons 4-6, 11 and 15.
Western blotting
The monoclonal antibody MAB377 (R&D Systems, Abingdon, UK) was used at 1:200. It had been obtained by immunization with recombinant human neuregulin1 isoform-b1 extracellular domain (amino acids 2-246, exons 2-6, 8 and part of 10), and is expected to detect most isoforms except sensory and motor neuron-derived factor and perhaps and glial growth factor II. Cell lysates were prepared in the presence of protease inhibitors according to Iyer et al. (2004) and analysed in 10% polyacrylamide gels. Monoclonal binding was detected with anti-mouse peroxidase conjugate (Dako, CA USA) at 1:1000 using the Amersham ECL system (Amersham Biosciences, Uppsala, Sweden). Re-probing for GAPDH used rabbit anti-GAPDH antibody AB9485 (Abcam, Cambridge, UK) at 1:1000.
Bisulphite sequencing DNA was bisulphite treated using EZ DNA methylation Gold kit (Zymo Research, Orange, CA, USA) according to the manufacturer's protocol. Two overlapping sections of the NRG1 CpG island were amplified by PCR from the bisulphitemodified DNA. Primers designed for bisulphite-modified DNA (MethPrimer at http://www.urogene.org/methprimer/) were MetHrgF5 (GGGGIAATTGAAAAAGAG) and MeHrgR1 (ACCCACCTAAACTCTAACTACC), located -452 and þ 106 from the translation start site, and MeHrgF3 (GAGGGATAAATTTTTTTTAAAT) and MeHrgR2 (CTAT CCCTTACCCTAAACTCTAAAC), located -94 and þ 329 from the translation start site (Figure 1a ). The PCR products were cloned using TOPO TA Cloning kit (Invitrogen), and 10 clones were sequenced.
For pyrosequencing the target sequence GCGGC GGCGGCTGCCGGACGATGGGAGCG was selected, 32 525 414 to 32 525 442 bp on reference sequence NCBI Builds 35 and 36. It was amplified by PCR using MetHrgF5 (used above) and MetHrgF4_Bio primer (5 0 biotinylated-ATTTAAAAAAAATTTATCCCTC). The biotinylated PCR product was bound to Streptavidin Sepharose HP (GE Healthcare Amersham, UK), denatured using a 0.2 M NaOH solution, washed with 10 mm Tris-acetate (pH 7.6) and then with 70% ethanol using Vacuum Prep Tool (Biotage, Uppsala, Sweden). The purified single-stranded PCR products were released at 80 1C in annealing buffer (20 mM Tris-acetate, 2 mM Mg-acetate; pH7.6), mixed with pyrosequencing primer MeHrgSeq_Pur1 (GAGGAGGTTAGGAGTTGA) and sequenced using the PSQ HS 96 pyrosequencing system and PyroMark MD system (Biotage) with the sequencing reagents, Pyro Gold reagents (Biotage). DNA methylation was quantified using PSQ HS 96A SNP software and Pyro Q-CpG software (Biotage). Pyrosequencing agreed with conventional bisulphite sequencing when six representative cell lines were reanalysed, the largest difference in average methylation over the 29-bp fragment being 12%.
Azacytidine treatment
Cell lines were treated with 1-5 mM 5-aza-2 0 -deoxycytidine for 96 h (MDA-MB-361) or 76 h (HCC1500).
Small interfering RNA (siRNA) knockdown
The siRNA constructs were designed to target exons 3 and 4, present in all transcripts that start at the exon 2 CpG island (two constructs) and exons 13, 14 and 17 that are in the cytoplasmic pro-apoptotic region. We could not design siRNAs to uniquely target the 'universal' exon, exon 8. Some siRNAs were not very potent in preliminary experiments and these were combined, to give three independent siRNA treatments for HB4a and two treatments for HCC1806. Constructs were generated according to Brummelkamp et al. (2002) . The oligos were: pSuperNRG1_13 (targeted to exon 13) 5 0 gatccccTCACCAT CCTAACCCACCCttcaagagaGGGTGGGTTAGGATGGTG GAtttttta and agcttaaaaaTCACCATCCTAACCCACCCtct cttgaaGGGTGGGTTAGGATGGTGAggg3 0 ; pSuperNRG1_94 (targeted to exon 14) 5 0 gatccccCCCATCACTCCACTACTG TttcaagagaACAGTAGTGGAGTGATGGGttttta3 0 and 5 0 ag cttaaaaaCCCATCACTCCACTACTGTtctcttgaaACAGTAG TGGAGTGATGGGggg3 0 ; pSuperNRG1_153 (exon 3) 5 0 gat ccccAAACTAGTCCTTCGGTGTGttcaagagaCACACCGAA GGACTAGTTTttttta3 0 and 5 0 agcttaaaaaAAACTAGTCCTT CGGTGTGtctcttgaaCACACCGAAGGACTAGTTTggg3 0 ; pSuperNRG1_380 (exon 4) 5 0 gatccccCACCATCGTGGAAT CAAACttcaagagaGTTTGATTCCACGATGGTGttttta3 0 and 5 0 agcttaaaaaCACCATCGTGGAATCAAACtctcttgaaGTTTGA TTCCACGATGGTGggg3 0 ; pSuperNRG1_14 (exon 14) 5 0 gatcc ccGAGAAGCAGAGACATCCTTttcaagagaAAGGATGTCTC TGCTTCTCttttta3 0 and 5 0 agcttaaaaaGAGAAGCAGAG ACATCCTTtctcttgaaAAGGATGTCTCTGCTTCTCggg3 0 ; and pSuperNRG1_17 (exon 17) 5 0 gatccccGAAACGACCCA AGACTACGttcaagagaCGTACTCTTGGGTCGTTTCttttta3 0 and 5 0 agcttaaaaaGAAACGACCCAAGACTACGtctcttgaa CGTACTCTTGGGTCGTTTCggg3 0 . The NRG1 target seq uences are indicated in capitals, and were designed using OligoEngine Workstation 2 (http://www.oligoengine.com). The annealed oligos were ligated into BglII and HindIII sites of the pSUPER.retro.puro (Brummelkamp et al., 2002) vector and inserts sequenced.
HB4A and HCC 1806 were transfected using lipofectamine (Invitrogen) according to the manufacturer 0 s protocol. Cells cultivated on a tissue culture flask (75 cm 2 ) were incubated with 32 ml lipofectamine together with pSuperNRG1_380 (exon 2) (2 mg), a mixture of pSuperNRG1_94 (1 mg) and pSu-perNRG1_153 (1 mg) targeting exons 2 and 14, and a mixture of pSuperNRG1_14 (1 mg) and pSuper NRG1_17 (1 mg), targeting exons 14 and 17, in 8 ml OptiMEM medium (Invitrogen) for 5 h at 37 1C in a CO 2 incubator, and then 8 ml complete medium with serum was added. Cells were selected in 5 mg/ml puromycin (Sigma, Poole, UK) for a month to select stably transfected cells. Two independent transfections were performed for each combination of constructs. pSUPER.retro.puro was used as a control.
For growth curves, cells were plated in a 6-well tissue culture plate, at two starting densities, and were trypsinized and counted with a Beckman-Coulter ViCell XR Imaging Hemacytometer (Beckman, Fullerton, CA, USA) in triplicates.
